Vice President of Pharmacovigilance
Immunic Therapeutics
Vice President of Pharmacovigilance
Immunic Therapeutics
Clinical-stage biopharma developing oral autoimmune therapies
Summary
We are seeking an accomplished Vice President of Global Drug Safety & Pharmacovigilance is an experienced healthcare professional (HCP) with expertise in good pharmacovigilance practices and international regulatory requirements (EMA/FDA/ICH). As the leader of the function, this individual is responsible for establishing and overseeing pharmacovigilance strategy & operations to ensure the safety of patients receiving company products.
Responsibilities
Develop and implement pharmacovigilance processes, policies, SOPs, and safety database/PV systems.
Lead cross-functional governance, benefit-risk assessment, signal detection, and risk management efforts.
Chair the executive safety review committee, oversee safety data exchange with partners, and contribute to industry-wide safety initiatives.
Partner with clinical development to integrate safety into protocols, risk management plans, and safety charters.
Provide PV oversight for regulatory filings (IND/BLA/MAA) - including Clinical Overviews, ISS, and RMPs - and review IBs, DSURs, and key CSR sections; participate in regulatory meetings as needed.
Lead medical review of ICSRs and oversee PV team operations, quality, and compliance with global safety regulations.
Monitor and assess CRO performance on pharmacovigilance activities.
Recruit, hire, train, mentor, and coach PV staff, and oversee project deliverables and performance evaluations.
Qualifications & Education
MD, with clinical and industry experience and a proven track record leading pharmacovigilance teams.
Minimum of 15 years' experience in drug safety and pharmacovigilance roles in the biotech or pharmaceutical industry.
Proven leadership expertise, including a track record of building and leading high-performing teams.
In-depth knowledge of global pharmacovigilance regulations and compliance requirements (EMA/FDA/ICH).
Strong leadership and strategic decision-making abilities to drive safety initiatives and ensure regulatory compliance.
Immunic Therapeutics is an Equal Opportunity Employer. We are committed to fostering a diverse, inclusive, and equitable workplace where all individuals are valued and respected. Employment decisions are based on qualifications, merit, and business needs, without regard to race, color, religion, gender, sexual orientation, national origin, disability, veteran status, or any other protected status.
Please note, Immunic does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between Immunic and the agency. Immunic will not pay any fees related to unsolicited resumes.
Clinical-stage biopharma developing oral autoimmune therapies
Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.
Explore more opportunities at Immunic Therapeutics